title: Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes.
authors.forename: Tomas
authors.initials: T
authors.lastname: Stulc
authors.forename: Zdislava
authors.initials: Z
authors.lastname: Kasalova
authors.forename: Hana
authors.initials: H
authors.lastname: Krejci
authors.forename: Radka
authors.initials: R
authors.lastname: Dolezalova
authors.forename: Richard
authors.initials: R
authors.lastname: Ceska
mesh_terms: D015415:Biomarkers / Q000097:blood; D003404:Creatinine / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006710:Homocysteine / Q000097:blood* / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D015415:Biomarkers; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D006710:Homocysteine; D003404:Creatinine